Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
<- Back to All Agents

SGN-LIV1A

Trade Name:
Status:
Currently Enrolling
Treatment Protocol:
SGN-LIV1A is administered once every 3 weeks (q3w) at 2.5 mg/kg for 12 weeks followed by AC (q2w or q3w) for an additional 4 weeks.
Date Entered I-SPY:
December 18, 2017
Date Left I-SPY:
No. Participants in Arm:
Graduating Subtypes:
Agent Description:

SGN-LIV1A (ladiratuzumab vedotin) is an antibody-drug conjugate (ADC) that we are developing for the treatment of breast cancer. Most metastatic breast cancers express LIV-1, which also has been detected in a number of other cancers, including melanoma, prostate, ovarian, uterine, and cervical cancers. Ladiratuzumab vedotin consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC agent is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response.

Notes:
Final pCR Probabilities:
Primary Manuscript:
 
abstractpdfdoi link